BACKGROUND: Prospective cohort studies contribute importantly to understanding the role of lifestyle, genetic, and other factors in chronic disease etiology. METHODS: The American Cancer Society (ACS) recruited a new prospective cohort study, Cancer Prevention Study 3 (CPS-3), between 2006 and 2013 from 35 states and Puerto Rico. Enrollment took place primarily at ACS community events and at community enrollment "drives." At enrollment sites, participants completed a brief survey that included an informed consent, identifying information necessary for follow-up, and key exposure information. They also provided a waist measure and a nonfasting blood sample. Most participants also completed a more comprehensive baseline survey at home that included extensive medical, lifestyle, and other information. Participants will be followed for incident cancers through linkage with state cancer registries and for cause-specific mortality through linkage with the National Death Index. RESULTS: In total, 303,682 participants were enrolled. Of these, 254,650 completed the baseline survey and are considered "fully" enrolled; they will be sent repeat surveys periodically for at least the next 20 years to update exposure information. The remaining participants (n 5 49,032) will not be asked to update exposure information but will be followed for outcomes. Twenty-three percent of participants were men, 17.3% reported a race or ethnicity other than "white," and the median age at enrollment was 47 years. CONCLUSIONS: CPS-3 will be a valuable resource for studies of cancer and other outcomes because of its size; its diversity with respect to age, ethnicity, and geography; and the availability of blood samples and detailed questionnaire information collected over time. Cancer 2017;123:2014-24. V C 2017 American Cancer Society.
INTRODUCTION
Prospective cohort studies have played an integral role in identifying and elucidating the role of lifestyle, environmental, genetic, and other factors in the etiology of chronic diseases and in public health efforts to reduce chronic disease morbidity and mortality. The American Cancer Society (ACS) has a long history of conducting large, prospective cohort studies dating back to the 1950s. [1] [2] [3] [4] Findings from ACS studies have contributed significantly to policies to reduce exposure to tobacco consumption 4 and air pollution 5 as well as evidence and guidelines for obesity, physical activity, and diet. 6, 7 Cancer Prevention Study II (CPS-II), the most recent ACS cohort study, was launched in 1982 and included nearly 1.2 million men and women who completed a lifestyle and medical history survey at enrollment and who continue to be followed for mortality outcomes, including death from cancer.
1 CPS-II resources have made seminal contributions, such as being the first study to comprehensively document associations of obesity with death from specific types of cancer. 8 A subset of 184,000 participants from CPS-II were enrolled in the CPS-II Nutrition Cohort in 1992 and 1993 and have been actively followed for both cancer incidence and mortality. 9 Since 1997, there have been numerous enhancements to this cohort, including the collection of new and updated medical and exposure information from biennial questionnaires (including a waist circumference measurement [1997] ), blood samples from approximately 40,000 participants (1998) (1999) (2000) (2001) , buccal cell samples from approximately 70,000 participants (2000) (2001) (2002) , and tumor tissues from participants diagnosed with breast, colorectal, prostate, and hematopoietic malignancies. 10 In the early 2000s, we began planning for CPS-3 for 2 primary reasons. First, CPS-II participants had a median age of 77 years in 2006 when CPS-3 pilot testing began. Enrolling a younger US study population was considered necessary both to monitor changes in the impact of established risk factors with lifetime exposure data (eg, smoking, obesity) and to identify new and emerging risk factors. Second, with the mapping of the human genome, 11 the value of collecting biospecimens on a large number of participants from epidemiologic cohorts was quickly appreciated by the scientific community. 12 In the past decade, the value of blood samples has expanded greatly with multiple " -omics" platforms. Analyses of banked biospecimens can allow for the integration of numerous biologic measures with traditional risk factors to better understand disease etiology and improve risk prediction. More recently, numerous large, prospective cohorts have been established in Asia, Europe, and Latin America that include more than 100,000 participants who provided blood samples at enrollment [13] [14] [15] ; however, there is a paucity of contemporary cohorts of similar size with biospecimens in the United States.
The ACS has been successful at recruiting large-scale studies because of its nationwide footprint in communities of all sizes and an extensive local volunteer and staff network that can support local enrollment opportunities. The volunteer relationship also allows for the recruitment of highly committed individuals. For example, response rates to biennial follow-up surveys to living CPS-II Nutrition Cohort participants have reached at least 88% for each survey cycle. These unique ACS attributes allow for cost-effective recruitment of individuals motivated to participate in a long-term cancer study. 16 Herein, we describe the design and conduct of the CPS-3 cohort to date, including enrollment methods, collection of questionnaire data and blood samples, and descriptive cohort characteristics.
MATERIALS AND METHODS

Study Objectives
The primary CPS-3 recruitment goal was to enroll 300,000 cancer-free US men and women ages 30 to 65 years, including collection of questionnaire data, waist circumference, and a blood sample from all participants by December 2013. By design, we enrolled men and women in their 30s and 40s, although relatively few of them are expected to develop cancer within 10 years of enrollment. In the long term, we believe this investment will yield valuable returns, because enrolling younger adults allows for repeated "real-time" assessments of exposure before most cancers are diagnosed. We plan to collect updated information by questionnaire from most participants approximately every 3 years and to follow all of them indefinitely for cause-specific mortality and cancer incidence.
We further aimed to enroll participants from the majority of states across the country, in both urban and rural areas. By doing so, we would be well positioned to broadly examine, for example, environmental exposures or aspects of built environment. Finally, we aimed to enroll at least 25% of participants from minority racial/ethnic groups, with a focus on African American and Hispanic recruitment. Collectively, African Americans and Hispanics account for approximately 30% of the US population, yet they are substantially under-represented in prospective cohort studies.
Enrollment Venues
Consistent with the past CPS cohorts, CPS-3 enrollment involved a partnership between the ACS Epidemiology Research Program, ACS leadership, local community staff, and volunteers nationwide. Participants were recruited in 35 states, Puerto Rico, and the District of Columbia, which collectively account for over 93% of the US population (Fig. 1) . Each of the 35 enrollment states was assigned a percentage of the 300,000 nationwide goal based on population size. The remaining 15 states were not included, because their population size was too small to permit cost-effective linkage with cancer registries (the primary planned method of identifying new cancers).
Enrollment took place at 2 types of venues: at ACS community fundraising events and at community enrollment "drives," which engaged broader segments of the community. The first type of venue included the ACS signature fundraising event called Relay for Life V R (hereinafter referred to as Relay) and Making Strides Against Breast Cancer (hereinafter referred to as Strides). Enrollees did not have to participate in the event to be eligible. Relays are organized by ACS volunteers and staff and last for 12 to 24 hours. These events occur nationwide in both small and large communities and offer the potential to effectively recruit from rural communities. By using registration data for these events, we were also able to select events that were large (>1000 participants) or racially/ ethnically diverse. Like Relay, Strides events are organized by ACS staff and volunteers, typically last 3 or 4 hours, involve a 3-mile to 5-mile walk, occur in urban communities, and tend to be more racially and ethnically diverse than Relay events. Other ACS event-related enrollments included a large ACS-sponsored advocacy event and regional volunteer "summits."
In 2006, we pilot tested the enrollment process at 6 Relay events (2 in each of 3 states). These pilot tests successfully demonstrated the feasibility of enrolling participants in partnership with trained ACS volunteers and of collecting, transporting, and processing blood samples collected in the field. Between 2007 and 2009, enrollment expanded to the remaining states such that, by 2010, enrollment was implemented nationwide. In total, enrollment occurred at 769 Relays, 35 Strides events, and 21 other ACS events, resulting in the recruitment of 122,359 participants.
In community-wide enrollment drives, ACS community, health system, faith-based, and corporate partners provided space on designated dates and times to host enrollment. Collectively, these drives ranged in length from 1 to 5 days, depending on the size and engagement of the community. These ACS partners provided enrollment opportunities (eg, at local YMCAs, hospitals, or places of employment and in communities ranging from small towns to large metropolitan areas), which were often more convenient to community members than eventbased enrollment sites. To enhance minority recruitment, several "targeted" enrollment sites were selected either as stand-alone community enrollment sites or as part of a community-wide drive. These included predominantly African American or Hispanic "mega" churches (those with greater than 1000 congregation members), events sponsored by historically black fraternity or sorority organizations, and lesbian/gay/bisexual/transgender community centers. In total, the approximately 2000 community-enrollment sessions (defined as a day of enrollment at a specific site) resulted in the recruitment of 174,233 participants. Between event-based and community enrollment drives, approximately 25,000 volunteers supported recruitment efforts. We also enrolled a relatively small number of adult children of female CPS-II Nutrition Cohort participants who provided their names and addresses. These adult children (n 5 28,388) were sent a single mailing that included an invitation to join CPS-3, a consent form, and a baseline survey. In total, 7028 men and women returned a consent form and a completed survey. Finally, 62 participants were enrolled because they signed a consent form and completed a baseline survey but did not subsequently attend an enrollment event. Of note, the above-mentioned participants did not complete an on-site enrollment survey or provide a blood sample.
All aspects of CPS-3 have been approved by the Emory University Institutional Review Board. In 2014, a Certificate of Confidentiality was obtained from the National Institutes of Health.
Enrollment Process
Each enrollment event required an approximately 6-month lead time to allow time for 5 Epidemiology Research Program study coordinators to identify and train staff and volunteers, build logistical infrastructure, and promote the event. Institutional Review Board-approved training and promotional materials included selfadministered training modules, training and promotional videos, promotional template e-mails, brochures, speaking points, press releases, presentations, enrollment process worksheets, and on-site signage.
Promotional activities occurred both before and during each event or enrollment drive. Often, extensive media coverage through newspaper, radio, or television aided in broad-scale promotion.
For event-based enrollment, interested individuals came to the event during the designated time window to enroll on a "walk-in" basis. For community drives, interested individuals could use an online system to schedule an enrollment appointment at the location, date, and time of their choosing. At enrollment, after verbally confirming eligibility (ages 30-65 years, never been diagnosed with cancer other than nonmelanoma skin cancer, and willingness to commit to a long-term study), trained volunteers directed enrollees to complete a brief sex-specific paper survey, referred to hereinafter as the "on-site" survey. Because participants often had limited time at the event, the on-site survey included an informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization and focused on the collection of identifying and key exposure information. More extensive data were collected on a second, "baseline" questionnaire, as described below.
After completing the on-site survey, the trained volunteer witnessed the consent to participate, checked contact information for completeness, and measured waist circumference. Waist circumference was measured with the participant standing with their feet together and stomach relaxed over a single layer of clothing. For men, the tape measure was placed at the navel and, for women, just above the navel. The measurement was recorded in centimeters, rounding down to the nearest centimeter. Each participant was then assigned a unique identifier using a sheet of cryogenic barcode labels to barcode survey materials and that would ultimately match the participant's blood-collection tubes. To capture timing of the blood sample with respect to the menstrual cycle, women who were still having menstrual periods were provided with a prepaid, barcoded postcard with instructions to write in the start date of her first menstrual period after enrollment and mail the postcard back. The enrollment process ended with participants directed to contracted phlebotomists from Quest Diagnostics, Inc., a large, nationwide clinical laboratory services company, for collection of a nonfasting blood sample. The full enrollment process, including blood sample collection, took approximately 20 to 30 minutes. In addition to the on-site enrollment survey, all participants were asked to complete the aforementioned baseline survey (on paper or online) at home that included extensive medical, lifestyle, and other information.
Survey Development
Participants were asked to complete 2 surveys, as described above. The on-site survey contained the informed consent; HIPAA authorization; identifying information necessary for follow-up, such as full name and Social Security number; and information relevant for blood analyses, such as time of last meal or medication and supplement use in the past month. We anticipated that some participants might not return the baseline survey; therefore, we also included questions about several key risk factors (medical history; weight; physical activity; smoking; and, for women, questions about reproductive and menstrual history) on the on-site survey. Additional questions were added to the on-site survey beginning in 2008 after pilot data confirmed that some participants did not complete the baseline survey.
The baseline survey was created by several working groups of ACS epidemiologists with feedback from other external experts. In some instances, questions from other cohorts' surveys were used (with or without modification), which has the benefit of facilitating future pooled analyses. For example, the physical activity section (adapted from the California Teachers' Study) 17 included questions about both current activity and past moderate and vigorous activity at specific ages. The baseline survey covered a wide variety of known or potential cancer risk factors, including anthropometry, medical history, use of selected medications and dietary supplements, reproductive history and use of exogenous hormones, cancer screening, family history of cancer, sun exposure, physical activity, occupation, tobacco and alcohol use, and demographic factors. Many of these are established risk factors for specific cancers, whereas others have not been extensively studied. We also inquired about early life exposures for several variables of research interest. For example, there were detailed questions about past and current sun exposure, including constitutional and behavioral factors, as well as residential history to comprehensively examine the association of sun exposure and vitamin D status with the risk of various cancers.
The baseline survey did not include a comprehensive dietary assessment instrument because of space constraints and to limit participant burden. Instead, the first followup survey cycle questionnaire (2015-2016) is devoted largely to comprehensive dietary assessment using a Harvard food frequency questionnaire 18, 19 modified for CPS-3 using data from 24-hour recalls and focus groups in diverse subsets of CPS-3 participants. Of note, the on-site enrollment survey contained 4 diet-related questions to allow broad assessment of dietary patterns (usual consumption of red and processed meat, vegetables, fruits, and whole grains).
Before enrollment, the baseline survey was administered to 35 ACS employees who were neither epidemiologists nor involved in survey development to obtain feedback on readability of survey questions. After revisions, the survey was administered during the 2006 pilot year, and responses from the approximately 1400 participants recruited in 2006 were examined to make additional modifications for 2007 onward. In 2007, the on-site and baseline surveys were translated into Spanish, because we expected that many of our enrollees would be Spanishspeaking, especially in Puerto Rico. In addition, an online version of the baseline survey, in English only, was developed.
Blood Collection and Processing
At each enrollment site, approximately 30 mL of blood was collected into three 10-mL Vacutainer tubes containing the anticoagulant ethylene diamine tetraacetic acid (EDTA), and approximately 6 mL of blood was collected into a tube containing the anticoagulant heparin. If there was difficulty in performing venipuncture (for example, because of small veins), then a maximum of 2 attempts were made.
Blood samples were stored in ice-water baths inside Styrofoam coolers until the end of the enrollment session to maintain the specimens at or below 48C. The coolers were transported by ground (or air in some instances) to 1 of 21 regional Quest Diagnostics laboratories (Fig. 1) for processing. At the laboratory, the 3 EDTA tubes were centrifuged, and plasma, red blood cells, and buffy coat were aliquoted into storage cryovials (see Fig. 2 ) and placed in a 2808C freezer. Whole blood from the heparin tube was aliquoted without centrifugation into cryovials containing 10% dimethyl sulfoxide (DMSO) to 90% whole blood, then gradually frozen to 2808C by placing cryovials in Styrofoam racks with lids for a minimum of 2 hours in the freezer before they were transferred to long-term storage boxes. All cryovials were labeled with cryogenic labels from the same, single-barcode sheet used at enrollment and were scanned before being placed in the freezer to obtain a date/time of processing. Specimens were expected to be processed and placed in freezers within 24 hours of collection.
After a minimum of 2 days in the 2808C freezer, specimens were shipped overnight with dry ice to our central biorepository, Fisher Bioservices Inc. On arrival at the biorepository, information on each cryovial (such as identifier and specimen type) was entered into a computerized tracking system, and specimens were then placed in liquid nitrogen vapor phase at approximately 21508C for longterm storage.
We conducted various quality-control pilot tests and collected quality-control samples from CPS-3 participants for use in future reliability testing. First, in 2006, we conducted a pilot study to test whether viable lymphocytes could be successfully recovered and immortalized with our collection protocol, and we were able to demonstrate that samples collected according to our protocol yielded viable transformed lymphocytes. 20 Second, DNA was extracted from buffy coat aliquots from approximately 3000 CPS-3 participants (recruited during 2006-2010). The extracted DNA was of high quality and substantial yield. The range of DNA yield was from 5.04 to 907.6 mg (median, 249.1 mg). Third, because our standard bloodcollection protocol involved several hours of delay between blood draw and freezing, we collected paired samples from 19 participants (12 women and 7 men) who enrolled at 1 of the pilot sites and contributed an extra tube of blood at that time. One EDTA tube per participant was transported immediately to the laboratory for Original Article processing, and the remaining sample from each participant was processed according to the standard protocol with all other specimens collected at the site. We also collected a repeat sample 19 to 24 months after the original collection from 15 participants to be able to examine longer term stability of different analytes. Finally, we had specimens from the participants who withdrew from the study (n 5 523) immediately after enrollment but allowed us to retain their de-identified blood sample for general quality-control use.
Follow-Up Surveys
Participants who completed the baseline survey (n 5 254,650) are considered "fully" enrolled and will be sent repeat surveys approximately every 3 years for at least the next 20 years to collect updated information on exposures. Participants will have the opportunity to complete follow-up surveys on paper or electronically as they did for the baseline survey. Participants who completed the on-site survey but did not return a baseline survey, even after repeated mailings (n 5 49,032), are considered only "partially" enrolled and will not be sent additional surveys, because they are not likely to be returned. All participants, whether fully or partially enrolled, will be followed for cancer and mortality outcomes and will receive an annual participant newsletter informing them of ongoing research activities within CPS-3 and to update address information.
In 2011, we sent a brief follow-up survey to participants who enrolled between 2006 and 2009 to: 1) evaluate response rates to follow-up surveys; 2) collect selfreported information on new cancer diagnoses; and 3) update information on key risk factors, such as weight, smoking status, and physical activity. The follow-up survey was mailed to 52,633 participants by routine US postal nonprofit service. Nonresponders were contacted up to 4 additional times. At completion, 45,205 had returned the survey (86% overall response rate).
Follow-Up for Cancer and Mortality Outcomes
Cause-specific mortality in the CPS-3 cohort will be ascertained through linkage with the computerized National Death Index, consistent with our practice for the CPS-II cohort. 21 Given the younger age distribution of the CPS-3 cohort, this linkage will initially be performed every 4 years, with increasing frequency as the cohort ages. The first National Death Index linkage is planned for 2017.
Cancer incidence in the CPS-3 cohort will be ascertained primarily through linkage with state cancer registries. The feasibility and validity of linkage with state cancer registries in CPS-3 has been demonstrated in a validation study that includes linkage with 23 state cancer registries. 22 Briefly, cancers self-reported by participants on the 2011 follow-up survey were verified by obtaining medical records. The sensitivity of registry linkage was then estimated as the proportion of cancer cases identified through self-report and verified with medical records that were independently detected by registry linkage. Overall sensitivity for cancer incidence was 89%. The majority of cancers missed by cancer registry linkage were melanoma or hematopoietic cancers, both sites known to be underreported to cancer registries. [23] [24] [25] [26] Estimated sensitivity for cancers other than melanoma and hematopoietic cancers was 94%.
The first cancer registry linkage of the full CPS-3 cohort is planned to start in 2018. CPS-3 participant information will be linked to the registries of each of the 35 states (plus the District of Columbia and Puerto Rico) where CPS-3 enrollment events were held. A small number of CPS-3 participants (<1%) live outside of the 35 states, the District of Columbia, and Puerto Rico where recruitment events were held. Because linkage with additional state cancer registries with few participants is not currently cost effective, self-reports of cancer by these CPS-3 participants will be verified by obtaining medical records, as is currently done in the CPS-II Nutrition Cohort. 23 After 5 years of follow-up, estimated statistical power to detect a relative risk 1.3 for a common exposure (30% prevalence) is greater than 95% for breast, prostate, and colorectal cancer. After 10 years of followup, there should also be sufficient statistical power for informative analyses of less common cancers, such as pancreatic or ovarian cancer.
We will collect normal and tumor tissue samples from individuals diagnosed with cancer at 5 sites (breast, colorectal, prostate, ovary, and hematologic) using an approach similar to that we currently use for the CPS-II Nutrition Cohort. 10 Briefly, when a participant self-reports 1 of these cancers, we will request their consent to obtain the medical record and treatment facility information so that we can collect their tissues from the facility where they are stored. At the time of consent, participants will also be asked to complete a brief survey to capture information related to their first course of treatment. For most participants, information on the first course of treatment will also be obtained from registry linkage.
RESULTS
Recruitment Characteristics
Between 2006 and 2013, 303,682 participants were enrolled. Of those, 254,650 completed the baseline survey and are "fully" enrolled, of whom 61.2% completed the survey online (English only), 38.1% completed a paper survey in English, and 0.7% completed a paper survey in Spanish (the Spanish-language version was available only as a paper survey). The mean time between on-site and baseline survey completion was 23 days, and 87% completed the survey between 3 months before and 3 months after enrollment.
We obtained blood specimens from 294,137 participants. The majority of participants for whom no blood was collected were adult children of CPS-II participants (n 5 7028); thus, we had a successful blood draw on 99.2% of participants who had the opportunity to provide a blood sample. The vast majority of specimens (97.3%) were processed within the required 24 hours from collection (median time to processing, 13 hours and 26 minutes). There were no sizeable differences in time to processing by laboratory or collection year (data not shown). Table 1 provides descriptive characteristics of the fully and partially enrolled participants; although fully enrolled participants are slightly more educated and have slightly healthier lifestyles, the 2 groups are generally similar. The median age of participants at enrollment was 47 years. Twenty-three percent of participants were men, compared with the goal of 35%; 17.3% of participants reported a race or ethnicity other than "white" (5% African American and 8% Hispanic), which was shy of our 25% goal, despite several efforts to enhance enrollment of these groups. CPS-3 recruitment goals for most states were met (data not shown). Eighty-seven percent of participants completed at least some college or a technical degree, and 73% were married. Relatively few participants were current smokers (approximately 7% of men and 6% of women), but many were former smokers (28% of men and 24% of women). The prevalence of obesity (body mass index 30 kg/m 2 ) was approximately 32% for men and 30% for women. Waist circumference was measured for 98% of participants, and the average 6 standard deviation waist circumference was 104 6 14.6 cm among men and 93 6 16.9 cm among women. Fifty-one percent of women reported regular menstrual cycles; among these women, 58% returned their menstrual postcard with a valid start date for their next menstrual cycle.
Baseline Characteristics
DISCUSSION
A major strength of CPS-3 is the ability to ascertain a wide range of lifestyle, behavioral, occupational, medical, reproductive, environmental, biologic, and other exposures over time, with the ability to capture new or changing exposures on follow-up questionnaires. We expect that CPS-3 will build on findings from CPS-II and other prospective studies and will help to clarify the evolving role of factors known to influence health, including smoking, obesity, physical activity, diet, and medications.
In addition, because CPS-3 is 1 of the largest contemporary cohort studies in the United States, it will be used to address new, emerging, or unanswered questions. For example, women in this cohort have had different reproductive experiences before, during, and after child-bearing years than women of previous generations, and there has been a large increase in the number of women using infertility medication and/or in vitro fertilization. 27 CPS-3 will be poised to examine the timing and patterns of use of both infertility medications and contraceptive use patterns in relation to the incidence of hormonally driven female cancers, including premenopausal breast cancer, because of the detailed information that will be captured over time and the sizeable number of women recruited.
The CPS-3 biospecimen repository will be valuable because of the large number of blood samples (including cryopreserved lymphocytes) collected within a single US cancer cohort, the younger age of the cohort (compared with CPS-II and many other cohorts with blood samples), multistate recruitment (including both urban and rural areas), and the ability to link this resource to extensive epidemiologic data. In addition, as biomarker discovery studies identify potentially important epigenetic, metabolomic and other "-omic" markers of cancer risk and their interactions with lifestyle exposures, CPS-3 can be an important resource to investigate these markers in relation to the risk of cancer and other diseases. Beyond disease etiology, CPS-3 offers the opportunity to contribute to studies of cancer survival and survivorship, because participants are followed for both cancer incidence and mortality. With serial collection of exposure information (including quality-of-life metrics) beginning before diagnosis, we will have the opportunity to address a wide range of important questions related to long-term survival and survivorship faced by the growing number (now over 15 million) 28 of cancer survivors in the United States.
One limitation of this study is that the proportion of men and nonwhite participants is lower than we aimed to recruit. Male participation was low whether in eventbased or community-wide enrollment venues (which included corporate locations with a higher proportion of men than events). Post-enrollment telephone and on-site interviews indicated that the blood draw was 1 possible barrier to participation, but the reasons for lower male participation rates are not fully understood.
We recognize the importance of studying diverse populations, despite challenges in recruitment, and thus set a recruitment target of 25% nonwhite participation, with an emphasis on African American and Hispanic recruitment (with a goal of 10% each). We ultimately did not meet this target despite significant efforts to support enrollment of nonwhite participants (17.3% actual enrollment: 7.8% Hispanic and 4.7% African American). For Hispanics, recruitment was boosted by conducting enrollment in Puerto Rico. Strategies to target minority enrollment included strategic partnerships with large minority leadership organizations (eg, African American fraternities), in which we engaged members to aid in study recruitment and conducted enrollments at regional or national meetings; the use of targeted promotional materials that were culturally focused to address issues of research mistrust in many diverse communities; and enrollment opportunities at places of worship. The most successful of these efforts was through faith-based outreach and recruitment, because individuals trusted information that was delivered by church leadership and shared a willingness to get involved if church leaders supported the study; however, further efforts are warranted to better understand how to successfully engage diverse populations in large-scale epidemiologic studies. Nonetheless, the absolute numbers of men and nonwhites are still quite large; and, both on its own and through pooling with other prospective cohorts, we expect that CPS-3 will make substantial contributions to understanding the etiology of cancer in diverse populations.
In conclusion, the American Cancer Society successfully recruited nearly 304,000 participants into its newest cohort study. With its large size; diversity with respect to age, race/ethnicity, and geography; and detailed survey data from multiple time points, blood samples, and tissue collection, CPS-3 will be a valuable resource for better understanding the causes of cancer and premature mortality in the United States in the 21st Century.
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